APA (7th ed.) Citation

Underhill, C., Hui, R., Links, M., Hawson, G., Chern, B., Yip, D., . . . Boyer, M. (2005). P-586 Phase II study of docetaxel and celecoxib as first or second linetherapy in patients with advanced NSCLC. Lung Cancer (01695002), 49, S272. https://doi.org/10.1016/s0169-5002(05)81079-7

Chicago Style (17th ed.) Citation

Underhill, C., R. Hui, M. Links, G. Hawson, B. Chern, D. Yip, T. Blackwell, C. Crombie, and M. Boyer. "P-586 Phase II Study of Docetaxel and Celecoxib as First or Second Linetherapy in Patients with Advanced NSCLC." Lung Cancer (01695002) 49 (2005): S272. https://doi.org/10.1016/s0169-5002(05)81079-7.

MLA (9th ed.) Citation

Underhill, C., et al. "P-586 Phase II Study of Docetaxel and Celecoxib as First or Second Linetherapy in Patients with Advanced NSCLC." Lung Cancer (01695002), vol. 49, 2005, p. S272, https://doi.org/10.1016/s0169-5002(05)81079-7.